» Articles » PMID: 29792889

ROS-triggered Degradable Iron-chelating Nanogels: Safely Improving Iron Elimination in Vivo

Overview
Specialty Pharmacology
Date 2018 May 25
PMID 29792889
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Iron-mediated generation of highly toxic Reactive Oxygen Species (ROS) plays a major role in the process leading to iron overload-related diseases. The long-term subcutaneous administration of Deferoxamine (DFO) is currently clinically-approved to improve patient symptoms and survival. However, non-specific toxicity and short circulation times of the drug in humans often leads to poor patient compliance. Herein, thioketal-based ROS-responsive polymeric nanogels containing DFO moieties (rNG-DFO) were designed to chelate iron and to degrade under oxidative stimuli into fragments <10 nm to enhance excretion of iron-bound chelates. Serum ferritin levels and iron concentrations in major organs of IO mice decreased following treatment with rNG-DFO, and fecal elimination of iron-bound chelates increased compared to free DFO. Furthermore, rNG-DFO decreased iron mediated oxidative stress levels in vitro and reduced iron-mediated inflammation in the liver of IO mice. The study confirms that ROS-responsive nanogels may serve as a promising alternative to DFO for safer and more efficient iron chelation therapy.

Citing Articles

Mitochondria-Targeted Biomaterials-Regulating Macrophage Polarization Opens New Perspectives for Disease Treatment.

Tian Z, Wang X, Chen S, Guo Z, Di J, Xiang C Int J Nanomedicine. 2025; 20:1509-1528.

PMID: 39925677 PMC: 11806677. DOI: 10.2147/IJN.S505591.


Nanogel: A versatile drug delivery system for the treatment of various diseases and their future perspective.

Gupta J, Sharma G Drug Deliv Transl Res. 2024; 15(2):455-482.

PMID: 39103593 DOI: 10.1007/s13346-024-01684-w.


Genetic Targets and Applications of Iron Chelators for Neurodegeneration with Brain Iron Accumulation.

Marupudi N, Xiong M ACS Bio Med Chem Au. 2024; 4(3):119-130.

PMID: 38911909 PMC: 11191567. DOI: 10.1021/acsbiomedchemau.3c00066.


Bile Acid-Targeted Hyaluronic Acid Nanoparticles for Enhanced Oral Absorption of Deferoxamine.

Agboluaje E, Cui S, Grimsey N, Xiong M AAPS J. 2024; 26(3):46.

PMID: 38609650 DOI: 10.1208/s12248-024-00911-z.


Regulating Type H Vessel Formation and Bone Metabolism via Bone-Targeting Oral Micro/Nano-Hydrogel Microspheres to Prevent Bone Loss.

Li J, Wei G, Liu G, Du Y, Zhang R, Wang A Adv Sci (Weinh). 2023; 10(15):e2207381.

PMID: 36967561 PMC: 10214236. DOI: 10.1002/advs.202207381.


References
1.
Gujja P, Rosing D, Tripodi D, Shizukuda Y . Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol. 2010; 56(13):1001-12. PMC: 2947953. DOI: 10.1016/j.jacc.2010.03.083. View

2.
Kremastinos D, Farmakis D . Iron overload cardiomyopathy in clinical practice. Circulation. 2011; 124(20):2253-63. DOI: 10.1161/CIRCULATIONAHA.111.050773. View

3.
Adams P, Deugnier Y, Moirand R, Brissot P . The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology. 1997; 25(1):162-6. DOI: 10.1002/hep.510250130. View

4.
Goodwin J, WHITTEN C . CHELATION OF FERROUS SULPHATE SOLUTIONS BY DESFERRIOXAMINE B. Nature. 1965; 205:281-3. DOI: 10.1038/205281b0. View

5.
Burkitt M, Mason R . Direct evidence for in vivo hydroxyl-radical generation in experimental iron overload: an ESR spin-trapping investigation. Proc Natl Acad Sci U S A. 1991; 88(19):8440-4. PMC: 52524. DOI: 10.1073/pnas.88.19.8440. View